Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Androgen Deprivation Therapy (ADT), Androgen-deprivation Therapy (ADT), Androgen-deprivation Therapy
Androgen deprivation therapy · 1 trial · 1 indication
Time to PSA progression was calculated from date of enrollment to the date of first documentation of PSA progression. As per Prostate Cancer Clinical Trials Working Group (PCWG2) criteria, PSA progression was defined as greater than or equal to (\>=) 25 percent (%) and \>=2 nanogram/milliliter (ng/mL) after 12 weeks (in case of no decline in PSA from Baseline), or first PSA increase that is \>=25% and \>=2 ng/mL above the nadir, and which was confirmed by a second value 3 or more weeks later (in case of decline of PSA from Baseline).
| Arm | Type | Description |
|---|---|---|
| Abiraterone Acetate | EXPERIMENTAL | Participants will receive abiraterone acetate 1000 milligram (mg) orally once daily along with prednisone 5 mg orally once daily and androgen deprivation therapy (ADT) as per Investigator's discretion until prostate-specific Antigen (PSA) progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| Abiraterone acetate | DRUG | Participants will receive abiraterone acetate 1000 mg (4\*250 mg tablets) orally once daily until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity. |
| Prednisone | DRUG | Participants will prednisone 5 mg orally once daily from Day 1 of Cycle 1 and continues until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity. |
| Androgen deprivation therapy (ADT) | DRUG | Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion. |
Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology * Prior therapy with diethylstilbestrol (DES) for castration resistant prostate cancer. Participants should demonstrate evidence of progressi...
Androgen deprivation therapy is used for prostatic neoplasms, specifically in the treatment of prostate cancer. It is being studied in the context of metastatic castration-resistant prostate cancer (mCRPC) in patients who have previously received diethylstilbestrol therapy. The therapy is under investigation as a treatment option for this patient population.
Androgen deprivation therapy is being developed by Johnson & Johnson, a company traded under the ticker JNJ. The therapy is currently in Phase 2 clinical development for the treatment of prostate cancer.
Androgen deprivation therapy is in Phase 2 clinical development. It is an investigational therapy and has not yet been approved by regulatory authorities. The therapy is being studied in a clinical trial for patients with metastatic castration-resistant prostate cancer.
Androgen deprivation therapy is associated with one completed clinical trial, NCT02217566. This Phase 2 study evaluated the therapy in participants with metastatic castration-resistant prostate cancer who were chemo-naive and had received prior diethylstilbestrol therapy. The trial was conducted in Brazil and enrolled 46 male participants aged 18 years and older.
Yes, Androgen deprivation therapy is also known as Androgen Deprivation Therapy (ADT) and Androgen-deprivation Therapy (ADT). These names refer to the same therapeutic approach being developed by Johnson & Johnson for the treatment of prostate cancer.